Regenesis Biomedical Advances Corporate Strategy by Appointing Vice President of... (g them to replicate and to produce natur...)

Regenesis Biomedical Advances Corporate Strategy by Appointing Vice President of Marketing

Date:5/1/2008

g them to replicate and to produce natural growth factors and other gene expression products, which facilitate reduction of the pain and edema associated with post-operative wound healing in soft tissues. We believe Provant is effective, economical, and easy-to-use.

About Regenesis Biomedical

Regenesis Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products. Regenesis developed, patented, and now markets the Provant Wound Therapy System. Our customers include health care facilities and providers that serve patients with wounds being treated by acute care hospitals, long- term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and wound care clinics.

Contact:

Regenesis Biomedical, Inc.

Media: Scott Robey, VP Marketing robey@regenesisbiomedical.com

Clinicians: Rick Isenberg, MD, VP Clinical Affairs

isenberg@regenesisbiomedical.com

Investors: Virginia Rybski, Acting President

rybski@regenesisbiomedical.com

http://www.regenesisbiomedical.com

480-970-4970

SOURCE Regenesis Biomedical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related biology technology :

1. Environmental Tectonics Corporations BioMedical Division Announces Sale of Two Hyperbaric Chambers
2. Boston Biomedical Research Institute Maintains Baa3 Rating from Moodys
3. SBT Acquisition Inc. Successfully Completes Tender Offer for Shares of Lifecore Biomedical, Inc.
4. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO) With $3.52 Price Target
5. LifeNet Health(R) Unveils New Biomedical Spine Implant
6. MIT researcher addresses biomedical engineering challenges
7. mNEMOSCIENCE GmbH Announces Global Licensing Agreement With Aporo Biomedical
8. Bookham to Enter Biomedical Illumination Market
9. ASH Holds a Special Symposium to Interest High School Students in Biomedical Research
10. New NIST mini-sensor may have biomedical and security applications
11. BioMedical Enterprises, Inc. (BME) Receives FDA Clearance for Spine Use of Its Memory Metal Implants

Post Your Comments:

(Date:11/6/2009)...ov. 6 Helix BioPharma Co...nnounced that John Docherty, president and chief o...Ford,s 6th annual Investor Summit on November 10, ...ity. Mr. Docherty will provide an overview of the...DOS47 and Topical Interferon Alpha-2b. The slide ...

(Date:11/6/2009)...RNewswire-FirstCall/ - Oncolytics Biotech Inc. (TS...) today announced updated results from a Phase II ...sarcomas metastatic to the lung in a poster presen...gy Society Meeting held in Miami Beach, Florida, f...entitled "A Phase II Study of Intravenous REOLYSIN...

(Date:11/5/2009)... Nov. 5 The endangered black-foote... U.S. This rare carnivore feeds on prairie dogs. ...and often entire population die-offs in towns occu... implemented a ferret breeding program and has bee...rmerly native habitat. Unfortunately, plague can ...

(Date:11/5/2009)...5 Transgenomic, Inc. (OT...results for the quarter ended September 30, 2009. ...he tables that follow. ,, Third Quarter 2009 ...or $0.01 per share for the third quarter of 2009 a...share for the third quarter of 2008. ,, Net sa...

Breaking Biology Technology:Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 2 Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 3 Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2 Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3 Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2 Transgenomic, Inc. Reports Third Quarter 2009 Results 2 Transgenomic, Inc. Reports Third Quarter 2009 Results 3 Transgenomic, Inc. Reports Third Quarter 2009 Results 4 Transgenomic, Inc. Reports Third Quarter 2009 Results 5 Transgenomic, Inc. Reports Third Quarter 2009 Results 6 Transgenomic, Inc. Reports Third Quarter 2009 Results 7

[0] Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th [0] Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting [0] Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret [0] Transgenomic, Inc. Reports Third Quarter 2009 Results

...tory affairs group based in Ann ... United BioSource Corporation,(UBC) today announce...d by,distinguished experts Mark Ammann, Pharm.D. a...an, the group will provide a full range of service...luding creating and,implementing development plans...

...IAN(TM) CRT-D and upgraded LATITUD...b. 25 Boston Scientific,Corporation (NYSE: BSX )...,(FDA) approval for three products in its Cardiac ...ONFIENT(TM) implantable cardioverter defibrillator...of sudden cardiac death, -- The LIVIAN(TM) cardi...

...Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced t...cal trial with AZ-004 (Staccato(R) loxapine). AZ-0...ped for the treatment of,acute agitation in patien...believes the novel, non-invasive nature and rapid ...aled loxapine administration via the Staccato,syst...

Other Biology Technology:United BioSource Expands Regulatory Affairs Capabilities 2 Boston Scientific Announces Three FDA Product Approvals for Its Cardiac Rhythm Management Business 2 Boston Scientific Announces Three FDA Product Approvals for Its Cardiac Rhythm Management Business 3 Boston Scientific Announces Three FDA Product Approvals for Its Cardiac Rhythm Management Business 4 Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2 Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3 Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4 Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5

United BioSource Expands Regulatory Affairs Capabilities Boston Scientific Announces Three FDA Product Approvals for Its Cardiac Rhythm Management Business Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)

(Date:11/4/2009)... , MADISON, N.J., Oct. 20 /PRNewswire-FirstCa...), the world,s leading provider of diagnostic test...the third quarter ended September 30, 2009, income...or $1.02 per diluted share, from $160 million, or ...2008. In 2008, third quarter results were reduced ...

(Date:11/4/2009)... , BEDFORD, Mass., Oct. 20 /PRNewswire-FirstC...pplier of broadband technology and biometrics soft...rd quarter ended September 30, 2009. ,, Mich...Officer, said, "Earlier today, we announced an agr... lines to Lantiq, a new fabless semiconductor comp...

(Date:11/4/2009)... , CARLSBAD, Calif., Oct. 23 ...ature biosample management for genomic discovery, ...David Wellis, Ph.D., GenVault,s President and CEO,...nce taking place on October 26th and 27th in La Jo... will provide an overview of the company together ...

[0] Quest Diagnostics Reports Strong Performance in Third Quarter 2009 [0] Aware, Inc. Reports Third Quarter 2009 Financial Results [0] GenVault Corporation to Present at the 2009 BIOCOM Investor Conference

...D researchers (1) showed that Epinephilus maculate...ledonia, was parasitized by 12 species of microsco...has just been confirmed also in the malabar groupe... species. If such a level of parasite diversity pr...f parasite species are in this ecosystem waiting t...

...OSTON (Sept. 5, 2007) As if being admitted to the...ed, are at higher risk of becoming infected with a...ficile). The toxins produced by C. difficile kill ...en, allowing the bacteria to use them as fuel. Thi...eath. Abraham Linc Sonenshein, PhD, and colleagues...

...Weinheim, September 04, 2007 - The term "biotechno... awe to fear and hostility. Alan McHughen from the...ow reviews at large the current state public knowl...c illiteracy and the role of the media. How is coe...fits from agricultural biotech only big companies...

Other Biology News:Coral reef fish harbor an unexpectedly high biodiversity of parasites 2 Coral reef fish harbor an unexpectedly high biodiversity of parasites 3 Curbing C. difficile's toxin production 2 How the public perceives biotech 2

Coral reef fish harbor an unexpectedly high biodiversity of parasites Curbing C. difficile's toxin production How the public perceives biotech

Single-stranded carrier DNA, 3 x 1 ml from Dualsystems Biotech AG

... Customer Peptide Synthesis , 20 Amino Acid leng...g will return to customer for future usage conjuga... Maintenance 102 days/each , Pre-immune bleed ...each , Test bleed (app. 5 ml) x1 /each , Pr...

6% PAGE/Urea Solution (19:1 Acrylamide/Bis + 6 M Urea) from Ambion

...unogen: Synthetic peptide derived from the interna...: Specific for the junctophilin-1 protein. Reacti...eletal muscle homogenates frozen mouse brain and s...otting Immunohistochemistry(froz) Immunofluorescen...

Biology Products:

Single-stranded carrier DNA, 3 x 1 ml from Dualsystems Biotech AG Peptide Antibody from Proteintech Group, Inc.6% PAGE/Urea Solution (19:1 Acrylamide/Bis + 6 M Urea) from Ambion Rabbit Anti-Mouse Junctophilin-1 (Mid) Monoclonal Antibody, Clone ZMD.471 from Invitrogen

Regenesis Biomedical Advances Corporate Strategy by Appointing Vice President of...(g them to replicate and to produce natur...)